Sinus
Acute Sinusitis Management
search
Acute Sinusitis Management
, Sinusitis Management, Acute Bacterial Rhinosinusitis
See Also
Acute Sinusitis
Management
Gene
ral Measures
Symptomatic relief
Warm, moist compresses over sinuses
Tylenol
Nasal Saline
spray (2% buffered saline) or
Neti Pot
Effective
Decongestant
Use pre-prepared solution or filtered, distilled or boiled water
Non-sterilized tap water rinses have been associated with amebic
Encephalitis
Yoder (2012) Clin Infect Dis 55(9): e79-85 [PubMed]
Also use as pretreatment prior to
Intranasal Steroid
Effective in recurrent
Sinusitis
when used daily
Rabago (2002) J Fam Pract 51:1049-55 [PubMed]
Papsin (2003) Can Fam Physician 49:168-73 [PubMed]
Mucolytic
Historically used, but evidence is lacking for benefit
Overall low side-effect profile and reasonable to trial
Guaifenesin
(e.g. Mucinex) 600 to 1200 mg orally twice daily
Topical Decongestant
s (Maximum of 3 days of use)
Oxymetazoline
(
Afrin
)
Avoid afrin (
Oxymetazoline
) in children
Risk of central alpha-2
Agonist
activity (
Clonidine
-like CNS depression)
Phenylephrine
(
Neo-Synephrine
)
If a nasal
Decongestant
is used in children,
Neo-Synephrine
(
Phenylephrine
) is preferred
Systemic Decongestant
s (e.g
Pseudoephedrine
)
Not recommended due to systemic adverse effects and adds little to symptomatic relief over other options
Avoid in
Hypertension
and cardiovascular disease
Limited course may be reasonable for refractory symptoms
Diversion to
Methamphetamine
production only reinforces a policy to discourage pseudophedrine availability and use
Consider 3 days of
Afrin
nasal spray for facial pain relief
Intranasal Steroid
s (treat for 3-6 weeks minimum if indicated)
Modest benefit even in
Acute Sinusitis
without underlying
Allergic Rhinitis
(NNT 15)
Chronic Sinusitis
Nasal Polyp
s
Dolor (2001) JAMA 286:3097-105 [PubMed]
Avoid
Antihistamine
s
Dry secretions
Impede osteomeatal complex drainage
Avoid
Systemic Corticosteroid
s (inffective, adverse effects) in
Acute Sinusitis
Head (2016) Cochrane Database Syst Rev (4): CD011992 [PubMed]
Management
Antibiotic
s
Precautions
Premature
Antibiotic
use (and
Antibiotic Overuse
) in
Acute Sinusitis
is common and unwarranted
Up to 70% of
Acute Sinusitis
<14 days resolves without
Antibiotic
s
Number Needed to Treat
(NNT) for
Antibiotic
in
Acute Sinusitis
benefit: 11-15
Number needed to harm (NNH) for
Antibiotic
in
Acute Sinusitis
adverse effects: 8
Indicated only in acute
Bacteria
l
Sinusitis
See
Acute Sinusitis
for Diagnosis
See
Sinusitis Prediction Rule
s
Only 10% of
Sinusitis
cases overall are
Bacteria
l
Persistent
Sinusitis
symptoms >10 days (
Bacteria
l in 60% of cases)
Moderate to severe unilateral facial pain for at least 3-4 days
May be associated with
Maxilla
ry
Toothache
Persistent
Fever
over 101 to 102 F
Upper respiratory symptoms for 5 to 6 days that resolved and then recurred (double-Hump Sign)
Delayed prescription may be considered (fill only for symptoms lasting >10-14 days)
Protocol
Antibiotic
course
Minimum course: 10 days (5-7 days may be sufficient)
Falagas (2009) Br J Clin Pharmacol 67(2): 161-71 [PubMed]
Consider longer course for persistent or recurrent symptoms suggestive of
Bacteria
l
Sinusitis
: 14 days
Change
Antibiotic
if no improvement in 7 days
Beta-Lactamase
resistance in acute cases: <30%
Beta-Lactamase
resistance in chronic cases: 40-50%
First-Line
Indications to start on first-line agents
Mild to moderate symptoms
No
Antibiotic Resistance
risk factors
No daycare exposure
No recent
Antibiotic
use in last 1-3 months
Immunosuppression
High local
Antibiotic Resistance
rates
Consider starting with high dose
Amoxicillin
or second-line
Antibiotic
s if higher risk for
Antibiotic Resistance
Guidelines as of 2015, recommend
Amoxicillin
-clavulanate as a first-line agent
Amoxicillin
Adult: 1000 mg orally twice daily
Consider
Augmentin
instead as first-line management in adults
Child: 90 mg/kg/day divided bid to tid (high dose)
Disadvantages: Misses
Beta-Lactamase
producers
Haemophilus
Influenza
e
Moraxella catarrhalis
Penicillin Resistant Pneumococcus
(increasing)
Amoxicillin
-Clavulanate (
Augmentin
): Standard Low Dose
Recommended as a first-line agent instead of
Amoxicillin
as of 2015 by IDSA for Acute Bacterial Rhinosinusitis
Covers
Haemophilus
Influenza
e and
Moraxella catarrhalis
which
Amoxicillin
misses
Child: 45 mg/kg/day divided every 12 hours
Adult:
Augmentin
875 mg orally twice daily (or 500 mg orally three times daily)
Second-Line
Indications to start on second-line agents (and to use high dose protocols, e.g.
Augmentin
high dose)
High endemic rates of invasive
Penicillin
resistant
Streptococcus Pneumoniae
(>10% rate)
Severe infection
Daycare attendance
Age <2 years or age over 65 years
Recent
Antibiotic
s in last month
Immunocompromised
Amoxicillin
-Clavulanate (
Augmentin
)
Child: 90 mg/kg/day divided twice daily (high dose recommended for second line management)
Adult
Low Dose:
Augmentin
875 mg orally twice daily (or 500 mg orally three times daily)
High Dose:
Augmentin
XR 1000/62.5 mg TWO tabs (or 2000/125 mg ONE tab) orally twice daily
Does not appear to benefit adults over standard dose in acute
Bacteria
l
Sinusitis
Gregory (2021) JAMA Netw Open 4(3):e212713 +PMID: 33755168 [PubMed]
Clindamycin
Indicated in
Penicillin Allergy
(hives,
Anaphylaxis
)
Child: 30-40 mg/kg/day orally divided 3-4 times daily
Cefuroxime
(
Zinacef
,
Ceftin
)
Adult: 500 mg orally twice daily
Child: 30 mg/kg/day orally divided twice daily
Cefpodoxime
(
Vantin
)
Adult: 200 mg orally twice daily
Child: 10 mg/kg/day orally once daily
Cefdinir
(
Omnicef
)
Adult: 300 mg PO bid or 600 mg orally once daily
Child: 14 mg/kg/day divided qd-bid
Avoid
Cefixime
Poor
Gram Positive Bacteria
coverage
Third Line
Consider adding
Metronidazole
(
Flagyl
) to second-line agents
Consider second-line agent for longer course (4 week)
Consider
CT Sinus
es
Consider Otolaryngology
Consultation
Fluoroquinolone
s (avoid under age 16 years, and those at higher risk of
Tendinopathy
,
Neuropathy
)
Levofloxacin
(
Levaquin
) 750 mg daily OR
Moxifloxacin
(
Avelox
) 400 mg daily
Consider
Parenteral
management in severe cases of hospitalized patients
Ceftriaxone
1-2 g IV every 24 hours OR
Ampicillin
-Sulbactam (
Unasyn
) 3 g IV every 6 hours OR
Levofloxacin
750 mg IV every 24 hours
Management
Penicillin
or
Cephalosporin
Allergy
Clindamycin
(children with
Penicillin Allergy
)
Dosing: 30-40 mg/kg/day divided three to four times daily
Consider in combination with
Rifampin
if severe
Poor efficacy against
Gram Negative Bacteria
Increasing resistance in
Haemophilus
and
Moraxella
Doxycycline
(avoid under age 8 years old)
Dosing: 100 mg orally twice daily for 5-7 days
Fluoroquinolone
s (avoid under age 16 years old)
See Third line agents above
Agents that are no longer recommended due to high resistance rates
Macrolide
Antibiotic
s (
Erythromycin
,
Azithromycin
,
Clarithromycin
)
Trimethoprim-Sulfamethoxazole (
Bactrim
,
Septra
)
Management
Referral Indications to ENT
See Also
Sinus Surgery
Sinusitis
refractory to maximal medical management
Recurrent
Acute Sinusitis
(>3-4 episodes per year)
Persistent
Chronic Sinusitis
Symptoms
Complicated
Sinusitis
Immunocompromised
patient
Toxic appearance or severe infection with high fever (e.g. >102 F or 39 C)
Osteomeatal obstruction or sinus obstruction due to anatomic defects
Fungal
Sinusitis
Nosocomial infection or other atypical
Bacteria
Suspected contiguous orbital or cerebral involvement
See red flag symptoms in
Acute Sinusitis
Sphenoid and
Frontal Sinus
itis are higher risk
Orbital Cellulitis
or intraorbital abscess
Subperiosteal abscess
Cavernous Sinus Thrombosis
Intracranial Abscess
Frontal bone
Osteomyelitis
(Pott Puffy Tumor)
References
(2019) Sanford Guide, accessed 1/21/2020
(2000) Otolaryngol Head Neck Surg 123:S1-S31 [PubMed]
(2001) Pediatrics 108:A24 [PubMed]
Aring (2011) Am Fam Physician 83(9): 1057-63 [PubMed]
Aring (2016) Am Fam Physician 94(2): 97-105 [PubMed]
Chow (2012) Clin Infect Dis 54(8):e72-e112 [PubMed]
Brook (2000) Laryngol 109:2-20 [PubMed]
Dowell (1998) Am Fam Physician 58:1113-23 [PubMed]
Osguthorpe (2001) Am Fam Physician 63:69-76 [PubMed]
Poole (1999) Am J Med 106(5A):38S-47S [PubMed]
Snow (2001) Ann Intern Med 134:495-7 [PubMed]
Type your search phrase here